top of page
JAZMINE
ZANIDATAMAB IN COMBINATION WITH TUCATINIB PLUS CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN HER2-POSITIVE ADVANCED BREAST CANCER
CLINICAL TRIAL DETAILS
TO DETERMINE THE RECOMMENDED PHASE II DOSE AND EVALUATE THE PRELIMINARY ANTITUMOR ACTIVITY OF ZANIDATAMAB IN COMBINATION WITH TUCATINIB PLUS CHEMOTHERAPY (CAPECITABINE OR ERIBULIN MESYLATE) IN PATIENTS WITH HER2-POSITIVE ADVANCED BREAST CANCER.
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
PRESS RELEASE
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
PHERGAIN SITES
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page